username425
Member
- Reaction score
- 7
From http://investors.kythera.com/releasedetail.cfm?ReleaseID=932602:
More on the link, but sounds like a good sign. Hopefully we see some results from guys who have already taken this soon.
[h=1]KYTHERA(R) Biopharmaceuticals Submits Investigational New Drug Application for KYTH-105 to Treat Androgenetic Alopecia, or Male Pattern Hair Loss[/h][h=2]Novel Oral Treatment Could Bring New Option to Large, Unsatisfied Market[/h]WESTLAKE VILLAGE, Calif., Sept. 22, 2015 (GLOBE NEWSWIRE) -- KYTHERA Biopharmaceuticals, Inc. (NASDAQ:KYTH) today announced it has submitted an Investigational New Drug Application (IND) to the U.S. Food and Drug Administration (FDA) for KYTH-105 (setipiprant) for treatment of androgenetic alopecia (Androgenetic Alopecia), or male pattern hair loss.KYTHERA plans to conduct a human proof-of-concept study to evaluate the efficacy and safety of setipiprant in male subjects with Androgenetic Alopecia, an inherited genetic disorder that is characterized by a recession of the hairline, hair thinning and progression to partial or complete baldness in men.[SUP]i[/SUP] Studies have shown that Androgenetic Alopecia has a significant impact on self-image, and men with the condition are likely to suffer from
psychosocial complications including depression, low self-esteem, an altered self-image and less frequent social engagement.[SUP]ii[/SUP] With more than 35 million American men experiencing hair loss,[SUP]iii[/SUP] the demand for a safe and effective treatment remains high.
"This submission is a significant milestone in the development of KYTH-105 for male pattern hair loss," said
Frederick Beddingfield, III, M.D., Ph.D., KYTHERA Chief Medical Officer. "KYTH-105 represents a unique scientific approach to the treatment of hair loss that has the potential to help millions of men achieve a positive self-image."
Setipiprant is a selective oral antagonist of the prostaglandin D[SUB]2[/SUB] (PGD[SUB]2[/SUB]) receptor - a possible key variable in hair loss - and is a well-characterized molecule supported by a large safety database. Setipiprant has been previously evaluated by Actelion Pharmaceuticals Ltd. in nine clinical studies as a potential allergic inflammation treatment, including a Phase III trial in seasonal allergic rhinitis patients and a Phase II proof-of-concept study in asthma patients, resulting in a safety database of more than 1,000 patients with no safety issues identified.
More on the link, but sounds like a good sign. Hopefully we see some results from guys who have already taken this soon.
